PRESCRIBING INFORMATION
Refer to Summary of Product Characteristics (SmPC) before prescribing

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to MSD (Tel: 01992 467272), UK.

PRESENTATION
Sinemet 12.5 mg/50 mg Tablets contains 12.5 mg of anhydrous carbidopa and 50 mg levodopa.
Sinemet 10 mg/100 mg Tablets contains 10 mg of anhydrous carbidopa and 100 mg levodopa.
Sinemet Plus 25 mg/100 mg Tablets contains 25 mg of anhydrous carbidopa and 100 mg levodopa.
Sinemet 25 mg/250 mg Tablets contains 25 mg of anhydrous carbidopa and 250 mg levodopa.
Sinemet CR 50 mg/200 mg Prolonged-Release Tablets contains 50 mg of anhydrous carbidopa and 200 mg levodopa.
Half Sinemet CR 25 mg/100 mg Prolonged-Release Tablets contains 25 mg of anhydrous carbidopa and 100 mg levodopa.

USES
Antiparkinsonian agent.
Sinemet CR & Half Sinemet CR: Idiopathic Parkinson’s disease, in particular to reduce off-period in patients previously treated with levodopa/decarboxylase inhibitors, or with levodopa alone and who have experienced motor fluctuations. Experience is limited with Sinemet CR and Half Sinemet CR in levodopa-naïve patients.

DOSAGE AND ADMINISTRATION
Consult the Summary of Product Characteristics.
Oral use. Patients ≤18 years: Not recommended.
Sinemet (excluding Sinemet CR & Half Sinemet CR): Determine optimum daily dose by careful titration. Sinemet tablets are available in a ratio of 1:4 or 1:10 of carbidopa to levodopa to provide a facility for fine dosage titration. Dopa-decarboxylase is fully inhibited (saturated) by carbidopa at doses between 70 and 100 mg a day.

Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting. Standard antiparkinsonian drugs, other than levodopa alone, may be continued while Sinemet/Sinemet CR/Half Sinemet CR are being administered. Adjust the dose if necessary. Monitor carefully during dose adjustment period. Involuntary movements, particularly blepharospasm, are a useful early sign of excess dosage. Patients not receiving levodopa: Initiate treatment with one tablet of Sinemet Plus t.d.s. Increase by one tablet of Sinemet 12.5 mg/50 mg or Sinemet Plus every day or every other day, if necessary, until a dosage equivalent of 8 tablets of Sinemet Plus a day is reached. If Sinemet 10 mg/100 mg or Sinemet 12.5 mg/50 mg is used, dosage may be initiated with one tablet t.d.s or q.d.s. Titration upwards may be required. Dose may be increased by one tablet every day or every other day until a total of 8 tablets (2 tablets q.d.s.) is reached. Fully effective doses usually are reached within 7 days. Sinemet 12.5 mg/50 mg or Sinemet 10 mg/100 mg may be used to facilitate individual dosage titration.

Patients receiving levodopa: Discontinue levodopa at least 12 hours (24 hours for slow-release preparations) before starting therapy with Sinemet. The dose of Sinemet should be approximately 20% of the previous daily dosage of levodopa. Patients taking <1,500 mg levodopa a day should take one tablet of Sinemet Plus t.d.s. or q.d.s. as required. Recommended starting dose for most patients taking more than 1,500 mg levodopa a day is one tablet of ‘Sinemet 25 mg/250 mg’ t.d.s. or q.d.s.

Maintenance: Therapy should be individualised and adjusted gradually according to response. Limited experience with a total daily dose ≥200 mg carbidopa.

Patients receiving levodopa with another decarboxylase inhibitor: Discontinue dosage at least 12 hours before Sinemet is started. The initial dosage of Sinemet should
provide the same levodopa dose as contained in the existing levodopa/decarboxylase inhibitor combination.

Sinemet CR & Half Sinemet CR: Administer as whole tablets only. Tablets should not be chewed, crushed, or halved. Standard antiparkinson drugs, other than levodopa alone, may be continued while Sinemet CR or Half Sinemet CR is administered. Adjust dose if necessary. Sinemet CR or Half Sinemet CR can be given with supplemental pyridoxine (vitamin B6). Patients currently treated with conventional levodopa/decarboxylase inhibitor combinations: When higher doses are given (≥900 mg/day), substitute Sinemet CR at an initial dose providing no more than approximately 10% more levodopa per day. Prolong dosing interval by 30 to 50% at intervals ranging from 4 to 12 hours. If divided doses are not equal, give the smaller dose at the end of the day. Titrate dose in line with clinical response. Patients currently treated with levodopa alone: Discontinue levodopa at least 8 hours before Sinemet CR is started. Patients with mild to moderate disease, the initial recommended dose is one tablet of Sinemet CR b.d.

Patients not receiving levodopa: Patients with mild to moderate disease: initial dose is one tablet of Sinemet CR b.d. Initial dose of levodopa, should not exceed 600 mg/day and should be given at intervals of less than six hours. Titration: Following initiation, doses and dosing intervals may be varied depending upon therapeutic response. Most patients have been adequately treated with 2 to 8 tablets per day of Sinemet CR given at divided doses of 4 to 12 hours during the waking day. Doses of up to 12 tablets per day over shorter intervals are not recommended. When given at intervals of less than 4 hours, or if the divided doses are unequal, the smaller doses should be given at the end of the day. An interval of at least three days between dosage adjustments is recommended. Maintenance: Periodic clinical evaluation is recommended. Adjust dose if necessary. Observe patients carefully if abrupt reduction or discontinuation is required, especially if the patient is receiving antipsychotics. Addition of other antiparkinson medication: Sinemet CR or Half Sinemet CR - Anticholinergic agents, dopamine agonists and amantadine can be given with Sinemet CR or Half Sinemet CR. Adjust dose if necessary. Sinemet (excluding Sinemet CR & Half Sinemet CR) - Other antiparkinsonian agents may be continued. Dose adjustment may be required.

CONTRA-INDICATIONS
Sinemet, Sinemet CR and Half Sinemet CR: Non-selective MAO inhibitors. Discontinue at least 2 weeks before starting dosing (may be co-administered with the manufacturer’s recommended dose of MAO Type B selective inhibitors). Patients with narrow-angle glaucoma, known hypersensitivity to any component of this medication, suspicious undiagnosed skin lesions or a history of melanoma, patients with severe psychoses. Sinemet CR or Half Sinemet CR should not be given when administration of a sympathomimetic amine is contraindicated.

PRECAUTIONS
Monitor carefully for development of mental changes, depression with suicidal tendencies, and other serious anti-social behaviour. Use caution in patients with psychoses. Not recommended for treatment of drug-induced extrapyramidal reactions. Dose reduction may be required if dyskinesias occurs in patients previously treated with levodopa alone. Use caution in patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of peptic ulcer disease. Monitor cardiac function in patients with a history of myocardial infarction who have residual, atrial, nodal, or ventricular arrhythmias, during the period of initial dosage adjustment and titration. Inform patients that sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. Advise caution while driving or operating machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Consider a dose reduction or stop treatment. Observe patients with a history of severe involuntary movements or psychotic episodes when treated with levodopa alone, as dose reduction may be required. A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. An abrupt dose reduction or withdrawal of Sinemet should be carefully observed, particularly in patients who are also receiving neuroleptics or antipsychotics. Consider the potential risk of developing Dopamine Dysregulation Syndrome. Monitor regularly for development of impulse control disorders; behavioural symptoms are:
pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating. Use with caution in patients with chronic wide-angle glaucoma. Ensure the intraocular pressure is well controlled and the patient monitored carefully for changes in intraocular pressure during therapy. Periodic evaluations of hepatic, haematopoetic, cardiovascular and renal function are recommended during extended therapy. Monitor for melanomas on a regular basis. Patients with a history of convulsions should be treated with caution.

Sinemet CR and Half Sinemet CR only: When patients are receiving levodopa monotherapy, levodopa must be discontinued at least 8 hours before therapy with Sinemet CR or Half Sinemet CR is started (at least 12 hours if slow-release levodopa has been administered). The onset of effect in patients with early morning dyskinesias may be slower than with conventional ‘Sinemet’.

Drug interactions:
Dopamine-depleting agents: Concomitant use with tetrabenzine or other drugs known to deplete monoamine stores is not recommended. Antihypertensive agents: Symptomatic postural hypotension. Dose adjustment of the antihypertensive agent may be required. Antidepressants: Hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants. Anticholinergics: may affect Sinemet's absorption. Iron: When ingested a decrease has been shown in the carbidopa and/or levodopa bioavailability. Other interactions: Dopamine D₂ receptor antagonists and isoniazid, may reduce the effects of levodopa. Effects reduced by phenytoin and papaverine. Patients should be carefully observed. Concomitant use with selegiline may be associated with severe orthostatic hypotension. The absorption of Sinemet may be impaired in some patients on a high protein diet.

Pregnancy and lactation: Do not use during pregnancy or breast-feeding.

SIDE EFFECTS - Refer to SPC for complete information on side effects
Most frequently reported: dyskinesias including choreiform, dystonic and other involuntary movements and nausea. Muscle twitching and blepharospasm may be taken as early signs to consider dosage reduction. Other adverse reactions: syncope, chest pain, anorexia, cardiac irregularities and/or palpitations, hypotensive episodes, hypertension, phlebitis, vomiting, gastrointestinal bleeding, duodenal ulcer, diarrhoea, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, angioedema, urticaria, pruritus, Henoch-Schönlein purpura, neuroleptic malignant syndrome, bradykinetic episodes, dizziness, paraesthesia, psychotic episodes including delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dopamine dysregulation syndrome, dementia, dream abnormalities, agitation, confusion, increased libido, somnolence, sudden sleep onset episodes, dyspnoea, alopecia.

Overdose: treat as per acute levodopa overdose. ECG monitoring should be instituted.

PACKAGE QUANTITIES AND BASIC NHS COST
Sinemet 12.5 mg/50 mg x 90 tablets: £6.28
Sinemet 10 mg/100 mg x 100 tablets: £7.30
Sinemet Plus 25 mg/100 mg x 100 tablets: £12.88
Sinemet 25 mg /250 mg x 100 tablets: £18.29
Sinemet CR 50mg/200 mg 60 Tablets: £11.60
Half Sinemet CR 25 mg/100 mg x 60 tablets:
Tablets: £11.60

Marketing Authorisation Numbers
Sinemet 12.5 mg/50 mg PL 00025/0226
Sinemet 10 mg/100 mg PL 00025/0084
Sinemet Plus 25 mg/100 mg PL 00025/0150
Sinemet 25 mg /250 mg PL 00025/0085
Sinemet CR 50mg/200 mg PL 00025/0269
Half Sinemet CR 25 mg/100 mg PL 00025/0287

Marketing Authorisation Holder
Merck Sharp & Dohme Limited,
Hertford Road, Hoddesdon, Hertfordshire
EN11 9BU, UK

Legal Category: POM

Date of review of prescribing information: January 2018

© Merck Sharp & Dohme Limited, 2018. All rights reserved.

PI.SEM&SEMCR.17.UK.6203.Editorial